These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2605831)

  • 1. [The excessive activity of cytochrome P450 system in ALS--the metabolic ratio of sparteine].
    Kaneko K; Atsumi T; Miyataka T
    Rinsho Shinkeigaku; 1989 Oct; 29(10):1251-5. PubMed ID: 2605831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphic sparteine metabolism and amyotrophic lateral sclerosis.
    Kaneko K; Atsumi T; Miyatake T
    J Neurol; 1989 Dec; 236(8):452-5. PubMed ID: 2614489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
    Ebner T; Meese CO; Eichelbaum M
    Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene.
    Pelclová D; Mráz J; Patzelová V; Pícková J; Pospísil J; Vodicková L; Hornychová M; Vejlupková J
    Int J Clin Pharmacol Ther; 1996 Jan; 34(1):38-42. PubMed ID: 8688995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biotransformation of sparteine in the Cuna American Indians of Panama].
    Arias TD; Jorge L; Lee D; Guerrero de Solís N; Escobar J; Barrantes R; Inaba T
    Rev Med Panama; 1986 Sep; 11(3):199-209. PubMed ID: 3468564
    [No Abstract]   [Full Text] [Related]  

  • 10. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
    Horai Y; Ishizaki T; Eichelbaum M; Hashimoto K; Chiba K; Dengler HJ
    Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A susceptible factor to acquire parkinsonism: sparteine oxidation polymorphism].
    Chiba K
    Rinsho Shinkeigaku; 1989 Dec; 29(12):1507-9. PubMed ID: 2630146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF; Hofmann U; Griese EU; Mikus G
    Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
    Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
    Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
    Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
    Osikowska-Evers B; Dayer P; Meyer UA; Robertz GM; Eichelbaum M
    Clin Pharmacol Ther; 1987 Mar; 41(3):320-5. PubMed ID: 3816020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The changes of clinical characteristics in 100 Japanese amyotrophic lateral sclerosis patients between 1980 and 2000].
    Kimura F; Shinoda K; Fujiwara S; Fujimura C; Nakajima H; Furutama D; Sugino M; Hanafusa T
    Rinsho Shinkeigaku; 2003 Jul; 43(7):385-91. PubMed ID: 14582363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.